Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400,...

The gap between BYD’s ambitions and the market’s mood is widening. Chairman Wang Chuanfu has laid out a five-year plan...

Redwood AI has multiplied its chemical reaction database fivefold to 21 million training examples and filed a new patent, yet...

The launch of Xiaomi’s 17T smartphone in India this week was supposed to herald a victory in its push upmarket....

The forces shaping Diginex’s future are pulling in opposite directions. On one side, a tsunami of global legislation is creating...

A new study lays bare a stark transatlantic gap in termination expenses: dismissing an employee in Germany costs the equivalent...

Kirkstone Metals is expanding its real estate in Canada's uranium-rich Athabasca Basin at a torrid pace, yet the market has...

AMD investors are confronting a stark divide. The stock has skidded 16% from its all-time high of €471.00 set in...

Nvidia is living two lives at once. In Washington, the chipmaker is sparring with Senator Elizabeth Warren over a subpoenaed...

Bayer is attempting to write a new chapter, one built on clinical proof rather than corporate promises. The German conglomerate's...